(CELC) Celcuity - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.821m USD | Total Return: 1185.9% in 12m
Avg Turnover: 123M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 26.5% YoY
Interest Coverage Ratio -5.3 is critical
Altman Z'' -3.15 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind, Pullback 52w
Celcuity Inc. (CELC) is a clinical-stage biotechnology firm headquartered in Minneapolis, Minnesota, specializing in targeted therapies for solid tumors. The company’s primary asset is Gedatolisib, a dual inhibitor targeting PI3K and mTOR pathways, currently being evaluated for advanced breast cancer and metastatic castration-resistant prostate cancer. This therapeutic approach aims to overcome treatment resistance by simultaneously blocking multiple signaling pathways within the tumor microenvironment.
The biotechnology sector often utilizes licensing agreements to advance clinical pipelines; Celcuity secured the worldwide rights to Gedatolisib through a strategic partnership with Pfizer Inc. Unlike traditional broad-spectrum chemotherapy, targeted therapies like those developed by Celcuity are designed to interfere with specific molecules involved in cancer growth and progression. Investors may find additional context on these clinical developments by exploring ValueRay.
Incorporated in 2011, the company focuses exclusively on the U.S. market for its current clinical trials. Its business model relies on the successful navigation of complex FDA regulatory hurdles and the potential commercialization of high-specificity oncology drugs.
- VIKTORIA-1 Phase 3 clinical trial results drive near-term stock valuation volatility
- FDA approval timeline for Gedatolisib determines future commercial revenue potential
- Strategic licensing agreement with Pfizer influences long-term royalty and milestone payments
- Research and development burn rate necessitates future capital raises or partnerships
- Expansion of Gedatolisib into prostate cancer markets increases total addressable market size
| Net Income: -192.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA 4.82 > 1.0 |
| NWC/Revenue: 244k% < 20% (prev 152k%; Δ 91.8k% < -1%) |
| CFO/TA -0.42 > 3% & CFO -172.5m > Net Income -192.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.5m) vs 12m ago 26.50% < -2% |
| Gross Margin: -8.44% > 18% (prev -0.13%; Δ -830.9% > 0.5%) |
| Asset Turnover: 0.05% > 50% (prev 0.06%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: -5.27 > 6 (EBITDA TTM -172.7m / Interest Expense TTM 32.8m) |
| A: 0.92 (Total Current Assets 408.9m - Total Current Liabilities 33.2m) / Total Assets 410.2m |
| B: -1.22 (Retained Earnings -501.7m / Total Assets 410.2m) |
| C: -0.55 (EBIT TTM -172.8m / Avg Total Assets 314.1m) |
| D: -1.41 (Book Value of Equity -501.7m / Total Liabilities 356.6m) |
| Altman-Z'' = -3.15 = D |
As of May 24, 2026, the stock is trading at USD 142.53 with a total of 641,160 shares traded.
Over the past week, the price has changed by +0.40%,
over one month by +12.91%,
over three months by +31.46% and
over the past year by +1185.86%.
Celcuity has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy CELC.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 169 | 18.6% |
Revenue TTM = 154k USD
EBIT TTM = -172.8m USD
EBITDA TTM = -172.7m USD
Long Term Debt = 323.4m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0k USD (from shortTermDebt, last quarter)
Debt = 323.5m USD (corrected: LT Debt 323.4m + ST Debt 13.0k) + Leases 13.0k
Net Debt = 178.3m USD (calculated: Debt 323.5m - CCE 145.2m)
Enterprise Value = 7.00b USD (6.82b + Debt 323.5m - CCE 145.2m)
Interest Coverage Ratio = -5.27 (Ebit TTM -172.8m / Interest Expense TTM 32.8m)
EV/FCF = -40.47x (Enterprise Value 7.00b / FCF TTM -172.9m)
FCF Yield = -2.47% (FCF TTM -172.9m / Enterprise Value 7.00b)
FCF Margin = -112k% (FCF TTM -172.9m / Revenue TTM 154k)
Net Margin = -125k% (Net Income TTM -192.9m / Revenue TTM 154k)
Gross Margin = -8.44% ((Revenue TTM 154k - Cost of Revenue TTM 167k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 17.06 (Enterprise Value 7.00b / Total Assets 410.2m)
Interest Expense / Debt = 10.15% (Interest Expense 32.8m / Debt 323.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -136.5m (EBIT -172.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.31 (Total Current Assets 408.9m / Total Current Liabilities 33.2m)
Debt / Equity = 6.04 (Debt 323.5m / totalStockholderEquity, last quarter 53.5m)
Debt / EBITDA = -1.03 (negative EBITDA) (Net Debt 178.3m / EBITDA -172.7m)
Debt / FCF = -1.03 (negative FCF - burning cash) (Net Debt 178.3m / FCF TTM -172.9m)
Total Stockholder Equity = 78.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.40% (Net Income -192.9m / Total Assets 410.2m)
RoE = -33.22% (Net Income TTM -192.9m / Total Stockholder Equity 580.6m)
RoCE = -19.12% (EBIT -172.8m / Capital Employed (Equity 580.6m + L.T.Debt 323.4m))
RoIC = -58.91% (negative operating profit) (NOPAT -136.5m / Invested Capital 231.8m)
WACC = 8.66% (E(6.82b)/V(7.14b) * Re(8.69%) + D(323.5m)/V(7.14b) * Rd(10.15%) * (1-Tc(0.21)))
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 32.53%
[DCF] Fair Price = unknown (Cash Flow -172.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.65 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.98 | Chg30d=+2.97% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=-1.08 | Chg30d=+0.00% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-3.53 | Chg30d=+6.61% | Revisions=N/A | GrowthEPS=-9.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.74 | Chg30d=+167.27% | Revisions=-20% | GrowthEPS=+121.0% | GrowthRev=+800.9%
[Analyst] Revisions Ratio: -20%